Abstract
In recent years, there has been an explosion of therapies for the treatment of melanoma, including BRAF mutation–guided therapy. With coverage by The ASCO Post, Lisa Kottschade, APRN, MSN, CNP, of the Mayo Clinic reviews clinical data supporting emerging targeted therapies and immunotherapies, and shares considerations on patient selection, education, and adverse event management.
